Shots:

• The ongoing BE BRIGHT- OLE trial evaluates the safety- tolerability- and efficacy of bimekizumab (q4w/q8w) in 989 patients with the mod. to sev. PsO
• The interim data showed that @16wks.- 9/10 patients achieved clear or almost clear skin (IGA 0/1)- 8/10 patients achieved complete skin clearance (PASI 100) and maintained responses through 2yrs. with continuous maintenance dosing
• Bimekizumab is an investigational humanized IgG1 mAb that selectively inhibits both IL-17A & IL-17F. The therapy is currently under the FDA’s review for the mod. to sev. PsO in adults while EC’s decision on MAA is expected within ~ 2mos of CHMP’s opinion

| Ref: PR Newswire | Image: Contract Pharma